Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity Article Source：Evogene Official Website https://evogene.com/newsroom/press-release/evogene-announces-successful-completion-of-phase-1-clinical-study-of-bmc128-a-rationally-designed-live-bacterial-product-in-combination-with-nivolumab-by-its-subsidiary-biomica/ REHOVOT, Israel, June 2, 2026 – Evogene Ltd. (“Evogene”) (Nasdaq/TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced s...

April 24, 2026 – Dr. William Chen, Chairman of Lishan Biotech, has added another honor to his name. At the 2025 Pudong New Area “Pearl Cup” Entrepreneurship Competition, Dr. Chen and his team won the “Most Promising Overseas Returnee Entrepreneurship Team Award” for their project, the “World-Class Live Biotherapeutic Product (LBP) Platform for Gut Microbiome.” The competition was hosted by Pudong Venture Capital Group and guided by the Pudong New Area Talent Work Bureau. It aimed to attract overseas and domestic tech talent entrepreneurship projects through a model of “competition-based evaluation and investment linkage.” Focusing on three leading industries—integrated circuits, biomedicine, and artificial intelligence—the competition drew numerous projects from home and...

Innovation Drives the Future——Though the Journey is Long, Perseverance Leads to Success Recently, Shanghai Lishan Biotech Co., Ltd. has received exciting news—it has officially been recognized as a National High-Tech Enterprise and has been awarded the "High-Tech Enterprise Certificate" jointly issued by the Shanghai Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Municipal Office of the State Administration of Taxation. This recognition marks that Lishan Biotech has met the national standards for high-tech enterprises in areas such as innovative drug development, technological innovation, and achievement commercialization, serving as a strong endorsement of the company's sustained innovation capabilities and scientific research strength.   AI-Empowered: The Innovation Engine f...

At the beginning of the Year of the Horse, on the afternoon of February 26th, the "New Overseas Chinese Innovation and Entrepreneurship in Shanghai" activity, organized by the Shanghai Federation of Returned Overseas Chinese to visit overseas Chinese enterprises and facilitate practical work, entered Zhangjiang Pharma Valley and held a thematic seminar at Lishan Biotech. A delegation comprising Qi Quansheng, Party Secretary and Chairman of the Shanghai Federation of Returned Overseas Chinese; Guo Qing, Vice Chairman of the Municipal Federation and concurrently Party Secretary and Chairman of the Pudong New Area Federation; and Cheng Dong, Chairman of the Zhangjiang Science City Federation, among others, visited the company. Li Zhi, Deputy Director of Corporate Communications at Junshi Biosciences, and Shang Jing, Executive D...